Wedbush initiated coverage of Spyre Therapeutics with an Outperform rating and $45 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics management to meet with BTIG
- Spyre Therapeutics reports Q2 EPS (86c), consensus (95c)
- Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Spyre Therapeutics management to meet virtually with BTIG
- Spyre Therapeutics initiated with an Outperform at Evercore ISI